DATATRAK International, Inc. (DTRK)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DATATRAK International, Inc. (DTRK) with AI Score 47/100 (Weak). DATATRAK International, Inc. provides unified clinical solutions for the clinical trials industry, offering a suite of software and consulting services. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026DATATRAK International, Inc. (DTRK) Healthcare & Pipeline Overview
DATATRAK International, Inc. delivers unified clinical trial solutions through its DATATRAK ONE platform, targeting contract research organizations, pharma, and biotech companies. With a high gross margin and focus on streamlining clinical trial processes, DATATRAK competes in the healthcare information services sector, offering consulting and SaaS solutions.
Investment Thesis
DATATRAK International presents a compelling, albeit speculative, investment case based on its specialized position within the clinical trial software market. The company's high gross margin of 81.7% suggests strong pricing power and efficient service delivery. With a P/E ratio of 0.64, the company may be undervalued relative to its earnings, though the low market cap warrants caution. Growth catalysts include expanding adoption of its DATATRAK ONE platform and strategic partnerships within the pharma and biotech sectors. However, potential risks include intense competition from larger players and the inherent volatility associated with OTC-traded stocks. Investors should carefully weigh the potential for growth against the risks associated with the company's size, market capitalization, and trading venue.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 81.7% indicates strong profitability and efficient cost management within its operations.
- P/E Ratio of 0.64 suggests potential undervaluation compared to its earnings, but requires further investigation due to the company's OTC status.
- Profit Margin of 171.0% reflects high profitability, but may be influenced by specific accounting practices or one-time events.
- The company's focus on unified clinical solutions addresses a critical need in the clinical trials industry, potentially driving future growth.
- DATATRAK ONE Unified Experience platform offers a comprehensive suite of tools, potentially increasing customer retention and attracting new clients.
Competitors & Peers
Strengths
- Unified platform offering comprehensive clinical trial solutions.
- High gross margin indicating efficient operations.
- Specialized expertise in the clinical trials industry.
- Established relationships with CROs and pharma companies.
Weaknesses
- Small market capitalization and limited resources.
- Reliance on a small number of clients.
- OTC listing may limit investor interest and liquidity.
- Limited geographic reach compared to larger competitors.
Catalysts
- Ongoing: Expansion of DATATRAK ONE platform adoption by CROs and pharmaceutical companies, driving recurring revenue growth.
- Ongoing: Strategic partnerships with technology providers to enhance the capabilities of the DATATRAK ONE platform.
- Upcoming: Potential regulatory changes favoring the adoption of unified clinical trial solutions, creating new market opportunities.
- Upcoming: Launch of new patient-centric solutions to improve patient engagement and data collection.
- Ongoing: Increasing demand for data analytics and AI in clinical trials, driving adoption of DATATRAK's advanced analytics capabilities.
Risks
- Potential: Intense competition from larger, well-established players with greater resources.
- Potential: Regulatory changes and evolving industry standards requiring significant investments in compliance.
- Potential: Economic downturns impacting clinical trial funding and delaying project timelines.
- Potential: Cybersecurity threats and data breaches compromising sensitive clinical trial data.
- Ongoing: Limited liquidity and price volatility associated with OTC-traded stocks.
Growth Opportunities
- Expansion into New Therapeutic Areas: DATATRAK can expand its market reach by targeting clinical trials in emerging therapeutic areas such as gene therapy and personalized medicine. These areas often require specialized data management and analysis capabilities, presenting an opportunity for DATATRAK to leverage its expertise and technology. The global market for gene therapy is projected to reach $13.8 billion by 2026, offering a substantial growth avenue.
- Strategic Partnerships with CROs: Collaborating with contract research organizations (CROs) can provide DATATRAK with access to a wider client base and increased market penetration. CROs play a crucial role in conducting clinical trials, and partnering with them can streamline the adoption of DATATRAK's platform. The global CRO market is expected to reach $69.7 billion by 2027, indicating the potential for mutually beneficial partnerships.
- Geographic Expansion into Emerging Markets: Entering emerging markets, such as Asia-Pacific and Latin America, can unlock new growth opportunities for DATATRAK. These regions are experiencing increasing clinical trial activity due to lower costs and growing patient populations. Tailoring its solutions to meet the specific regulatory and operational requirements of these markets can provide a competitive advantage.
- Enhancing Data Analytics Capabilities: Investing in advanced data analytics and artificial intelligence (AI) can enhance the value proposition of DATATRAK's platform. By providing clients with deeper insights into clinical trial data, DATATRAK can improve trial efficiency and outcomes. The market for AI in healthcare is projected to reach $45.2 billion by 2026, highlighting the potential for innovation in this area.
- Focus on Patient-Centric Solutions: Developing patient-centric solutions, such as mobile apps and remote monitoring tools, can improve patient engagement and data collection in clinical trials. These solutions can enhance the patient experience and provide researchers with more comprehensive data. The market for mobile health (mHealth) is expected to reach $247.4 billion by 2027, indicating the growing importance of patient-centric technologies.
Opportunities
- Expansion into new therapeutic areas and emerging markets.
- Strategic partnerships with CROs and technology providers.
- Development of patient-centric solutions.
- Adoption of advanced data analytics and AI.
Threats
- Intense competition from larger, well-established players.
- Regulatory changes and evolving industry standards.
- Economic downturns impacting clinical trial funding.
- Cybersecurity threats and data breaches.
Competitive Advantages
- Specialized Expertise: Deep understanding of the clinical trials industry and its specific needs.
- Integrated Platform: DATATRAK ONE Unified Experience offers a comprehensive suite of tools, creating a sticky solution for clients.
- Long-Term Relationships: Building strong relationships with CROs and pharma companies can lead to recurring revenue and customer loyalty.
- Proprietary Technology: The company's proprietary software and algorithms provide a competitive edge.
About DTRK
Founded in 1991, DATATRAK International, Inc. has evolved into a technology and services company focused on providing unified clinical solutions for the clinical trials industry. Headquartered in Mayfield Heights, Ohio, the company offers the DATATRAK ONE Unified Experience, a comprehensive clinical enterprise solution that enables clinical users and service providers to design, deliver, and manage clinical trials efficiently. This platform integrates various tools and services, including UX CTMS 360 for trial planning and management, UX Trial for streamlined design-to-deployment, UX EDC & Medical Coding for data capture, UX Randomization and Trial Supply Management, UX Patient Data Capture, UX Safety, and UX Training. DATATRAK's solutions cater to contract research organizations (CROs), pharmaceutical and biotech companies, and clinical trial device companies, providing them with the technology and support needed to navigate the complexities of clinical research. In addition to its software offerings, DATATRAK provides clinical consulting services, encompassing training, support, a learning center, SaaS hosting, standards, and trial design assistance, further solidifying its position as a comprehensive solution provider in the clinical trials space.
What They Do
- Provides a unified clinical enterprise solution called DATATRAK ONE Unified Experience.
- Offers software for designing, delivering, and managing clinical trials.
- Provides UX CTMS 360 for planning and managing clinical trials.
- Offers UX EDC & Medical Coding for capturing and delivering clinical trial data.
- Provides UX Randomization and Trial Supply Management to randomize patients and automate supply management.
- Offers UX Patient Data Capture, UX Safety, and UX Training solutions.
Business Model
- Software as a Service (SaaS): Provides access to its DATATRAK ONE platform on a subscription basis.
- Clinical Consulting Services: Offers training, support, and trial design services.
- License Fees: Potentially generates revenue through licensing its software to clients.
- Hosting Services: Provides Software as a Service hosting for clients.
Industry Context
DATATRAK International operates within the healthcare information services industry, a sector experiencing growth driven by the increasing complexity and cost of clinical trials. The market is characterized by a mix of large, established players and smaller, specialized firms. DATATRAK's focus on unified clinical solutions positions it to capitalize on the demand for streamlined and efficient trial management. However, the company faces competition from larger companies with greater resources and broader product offerings. The industry is also subject to regulatory changes and technological advancements, requiring companies to continuously innovate and adapt.
Key Customers
- Contract Research Organizations (CROs)
- Pharmaceutical Companies
- Biotech Companies
- Clinical Trial Device Companies
Financials
Chart & Info
DATATRAK International, Inc. (DTRK) stock price: Price data unavailable
Latest News
-
Datatrak and TAILRD Heart Announce Collaboration to Advance Ai‑Driven Healthcare and Life Sciences Clinical Research
Yahoo! Finance: DTRK News · Mar 16, 2026
-
DATATRAK ePRO/eCOA Solution Expands Decentralized Trial Platform
Yahoo! Finance: DTRK News · Mar 10, 2026
-
DATATRAK Standalone eConsent Accelerates Clinical Trials
accessnewswire.com · Feb 26, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DTRK.
Price Targets
Wall Street price target analysis for DTRK.
MoonshotScore
What does this score mean?
The MoonshotScore rates DTRK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Datatrak and TAILRD Heart Announce Collaboration to Advance Ai‑Driven Healthcare and Life Sciences Clinical Research
DATATRAK ePRO/eCOA Solution Expands Decentralized Trial Platform
DATATRAK Standalone eConsent Accelerates Clinical Trials
Leadership: Alex Tabatabai
Unknown
Information on Alex Tabatabai's background is not available in the provided data. Without additional context, it's difficult to provide a comprehensive profile. More information is needed to assess his career history, education, and previous roles.
Track Record: Information on Alex Tabatabai's track record is not available in the provided data. Without additional context, it's difficult to assess his key achievements, strategic decisions, and company milestones under their leadership.
DTRK OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DATATRAK International may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and greater price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: OTC companies may have less stringent reporting requirements, making it difficult to assess their financial health.
- Lower Liquidity: Trading volumes may be thin, leading to wider bid-ask spreads and increased price volatility.
- Higher Potential for Fraud: The OTC market is subject to less regulatory oversight, increasing the risk of fraudulent schemes.
- Limited Investor Protection: Investors may have fewer legal protections compared to those investing in companies listed on major exchanges.
- Price Volatility: OTC stocks can be more susceptible to price swings due to lower trading volumes and market capitalization.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile for any disclosures or warnings.
- Consult with a financial advisor to assess the risks and potential rewards.
- Understand the company's revenue sources and profitability.
- Check for any legal or regulatory issues involving the company.
- The company has been in operation since 1991.
- DATATRAK serves contract research organizations, pharma, and biotech companies.
- The company offers a suite of products and services for the clinical trials industry.
- DATATRAK has a high gross margin, suggesting a viable business model.
- The company has a positive profit margin, indicating profitability.
DATATRAK International, Inc. Stock: Key Questions Answered
What does DATATRAK International, Inc. do?
DATATRAK International, Inc. provides unified clinical solutions and related services for the clinical trials industry. The company's flagship product, the DATATRAK ONE Unified Experience, is a clinical enterprise solution that allows clinical users and service providers to design, deliver, and manage clinical trials. Their offerings include software for planning, data capture, randomization, and safety management, as well as clinical consulting services. DATATRAK serves contract research organizations, pharma and biotech companies, and clinical trial device companies, aiming to streamline and optimize the clinical trial process.
What do analysts say about DTRK stock?
As of 2026-03-16, formal analyst ratings for DATATRAK International, Inc. (DTRK) are unavailable, likely due to its OTC listing and small market capitalization. Key valuation metrics include a P/E ratio of 0.64 and a high gross margin of 81.7%. Growth considerations center on the adoption of its DATATRAK ONE platform and expansion into new therapeutic areas. Investors should conduct their own due diligence and consider the risks associated with OTC-traded stocks before making any investment decisions.
What are the main risks for DTRK?
DATATRAK International, Inc. faces several risks inherent to its size, industry, and OTC listing. Competition from larger, well-established players with greater resources poses a significant threat. Regulatory changes and evolving industry standards may require substantial investments in compliance. Economic downturns could impact clinical trial funding, delaying projects. Cybersecurity threats and data breaches could compromise sensitive clinical trial data. The limited liquidity and price volatility associated with OTC-traded stocks also present risks for investors.
What are the key factors to evaluate for DTRK?
DATATRAK International, Inc. (DTRK) currently holds an AI score of 47/100, indicating low score. Key strength: Unified platform offering comprehensive clinical trial solutions.. Primary risk to monitor: Potential: Intense competition from larger, well-established players with greater resources.. This is not financial advice.
How frequently does DTRK data refresh on this page?
DTRK prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DTRK's recent stock price performance?
Recent price movement in DATATRAK International, Inc. (DTRK) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Unified platform offering comprehensive clinical trial solutions.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DTRK overvalued or undervalued right now?
Determining whether DATATRAK International, Inc. (DTRK) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DTRK?
Before investing in DATATRAK International, Inc. (DTRK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights in the future.